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Abstract
This study describes the successful delivery of helper-dependent adenoviral vectors to the mouse retina with long
term and robust levels of reporter expression in the retina without apparent adverse effects. Since these vectors
have a large cloning capacity, they have great potential to extend the success of gene therapy achieved using the
adeno-associated viral vector.
Background
The eye has several unique features that make it a well
suited target organ for gene therapy. It has a highly
compartmentalised structure which allows for the effi-
cient delivery of a small volume of vector suspension to
a specific subset of cells. The precise targeting of a par-
ticular cell type minimises viral dissemination and
unwanted systemic effects. Additionally, immune
responses resulting from intraocular administration are
attenuated compared to those following systemic admin-
istration because the eye has both physical barriers as
well as an internal environment that promotes tissue
preservation and protects against harmful inflammatory
responses that can limit transgene expression. Lastly, a
wide range of well characterized animal models are
available for studies of eye disease progression [1,2].
Several recent gene therapy trials have brought clinical
benefits to patients with Leber’sC o n g e n i t a lA m a u r o s i s ,
a severe childhood retinal dystrophy [3-6]. Currently,
the majority of eye gene therapy trials are carried out by
using the adeno-associated virus (AAV). Although ear-
lier work with AAV was shown a lag between viral vec-
tor injection and transgene expression, the self-
complementary AAV (scAAV) has been shown to
express the transgene in as little as one-day after injec-
tion, and can transfect the photoreceptor cells in addi-
tion to the RPE [7]. However, the limited cloning
capacity of the AAV vector (4.7 kb) [8] is a major
obstacle to delivery of large therapeutic genes or genes
with long DNA regulatory elements that has yet to be
overcome. Although some have attempted to deliver
large genes using AAV[9,10], the latest studies have
revealed that the expression of the transgenes was a
result of co-infection and recombination within target
cells [11]. The existence of retinal diseases involving
genes beyond the AAV’s cloning capacity encourages
studies of potential viral gene therapy vectors beyond
AAV. For example, ABCA4 is a member of the ATP-
binding cassette transporter sub-family, mutations of
which are linked to Stargardt macular dystrophy. As
another example, CEP290, a gene encoding a 290 kDa
centrosomal protein, is associated with a frequent form
of Leber’s Congenital Amaurosis (LCA10). The cDNAs
of these genes are 6.8 kb and 7.4 kb respectively, pre-
cluding the use of AAV vectors even before considera-
tion of regulatory elements. Thus, it is important to
develop alternative vectors that have a large cloning
capacity, the ability to transduce non-dividing cells in
the post-mitotic retina, and a low immunogenicity to
allow sustained long-term transgene expression. The
helper-dependent adenoviral (HD-Ad) vector presents
all these characteristics which make it an ideal candidate
for retinal gene therapy.
HD-Ad vector, also known as the gutless, gutted, or
high-capacity Ad vector, has been developed with signif-
icant improvements in the safety and delivery efficiency
after many changes made to the first generation adeno-
viral (FG-Ad) vectors [12-16]. The main difference in
genome composition between the HD-Ad vector and its
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and ψ sequences necessary for vector replication and
packaging, respectively [17,18]. This strategy prevents
the production of any viral proteins which in turn sig-
nificantly reduces the cytotoxic T lymphocyte (CTL)
response brought upon by viral gene expression [19-21].
A minimized immune response reduces toxicity to host
cells, delays vector clearance, and promotes long-term
transgene expression. In fact, upon HD-Ad injection
through the tail vein of mice, transgene expression in
livers has been shown to have life-long persistence [22].
However, very little is known about the utility of HD-
Ad vectors in retinal gene therapy [23,24], especially
regarding the delivery of HD-Ad into the subretinal
space[19,25]. We hypothesized that the HD-Ad system
can be used to deliver transgenes into retinal pigment
epithelial (RPE) and photoreceptor (PR) cells.
We performed extensive analyses of HD-Ad vector
delivery to mouse subretinal space using LacZ as a
reporter gene and found that the HD-Ad elicits trans-
gene expression for a minimum of 2 months with no
sign of decrease in expression. We also observed a dose
response in reporter gene expression. Our results show
that HD-Ad vectors have great potential to extend the
success of eye gene therapy to applications which
require vectors for delivering large genes or regulatory
elements.
Results and discussion
Currently, retinal gene therapy trials are carried out with
AAV vectors [26] and little is known about the feasibil-
ity of HD-Ad vector as a vehicle for gene delivery to
human retinal cells. To examine the potential of HD-Ad
vectors to be used for retinal gene therapy, mice were
given subretinal injections with the CMV-LacZ HD-Ad
vector. At 4 different time points, the retinal expression
of the reporter gene was determined via X-gal staining.
One week following injection with HD-Ad-CMV-LacZ
at 1 × 10
8 vector particles (vp)/eye, mice showed robust
transgene expression along the retinal layer (Figure 1A).
The X-gal positive areas were seen in the RPE predomi-
nantly, with sporadic expression found in the proximal
regions of the outer segments (OS). Two months post-
injection (Figure 1D), the furthest time point tested for
the HD-Ad-CMV-LacZ injected mice, trends in expres-
sion were comparable to the 1 week time point. X-gal
staining was present along the retinal layer with the
majority of expression in the RPE layer and little expres-
sion in the OS of the PR cells.
HD-Ad vectors have attributes that make them desir-
able in gene therapy trials. Due to their genome being
devoid of all viral coding genes [17,18], little or no CTL
response arises [19-21], and the vector can persist in
host cells for a very long time where they stay in episo-
mal form [27]. Since retinal cells are terminally
Figure 1 Retinal expression of LacZ reporter. Eyes were processed for X-gal staining and cut at serial sections of 6 μm and counterstained
with neutral red. Expression was detected at 1 week (A), 2 weeks (B), 1 month (C), and 2 months (D) in the RPE layer of the retina. Some
expression was also detected in the proximal OS. Control (E) with no vector injection reveals no b-galactosidase activity. RPE, retinal pigment
epithelium; OS, outer segments; ONL, outer nuclear layer; INL, inner nuclear layer.
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somes is unlikely for HD-Ad vectors. Furthermore, since
t h eg e n o m ei sn o n - i n t e g r a t i ng, there is minimal risk of
insertional mutagenesis [2 7 ] .A l t h o u g hw eo n l ye x a m -
ined reporter expression up to two months, we predict
that it would continually persist had further time points
been examined.
Transgene expression was detected in mouse retina
three days following intraocular injections with HD-Ad
vectors [19,25]. Our results show that onset of maxi-
mum gene expression occurred no later than 1 week
post-injection. The lack of delay for transgene expres-
sion makes HD-Ad vectors superior if immediate trans-
gene expression is desired. For example, acute damage
by physical trauma to the eye resulting in fast retinal
cell deterioration will require a vector that quickly deli-
vers survival factors to rescue rapidly dying cells. The
delivery of various neurotrophic factors, growth factors,
and cytokines protect neurons from cell death in these
instances including BDNF, CNTF, neurotrophin-3 and
-4, and bFGF [28-31].
To examine the effect of viral vector dosage on trans-
gene expression, we injected mice with 3 different viral
vector doses and evaluated reporter gene expression
levels. At the lowest vector dose of HD-Ad-CMV-LacZ,
1×1 0
7 vp/eye, transgene expression was detected (Fig-
ure 2B), but consistency of expression throughout the
entire retina was not observed as only several areas
around the retina showed b-galactosidase activity. Serial
sectioning of tissues at this dose revealed that expres-
sion was absent from a large proportion of the retina
(Figure 2F). Also, expression of the transgene was con-
fined to the RPE layer of the retina (Figure 2M) and
absent from PR cells.
At 1 × 10
8 vp/eye, significant LacZ expression was
observed throughout the retina (Figure 2C and 2G).
Serial sectioning of tissues in this group reveals consis-
tent and widespread X-gal staining all along the RPE
layer (Figure 2G and 2N). The highest vector concentra-
tion, 1 × 10
9 vp/eye resulted in more wide-spread X-gal
staining (Figure 2H) without affecting the histology (Fig-
ure 2D). Expression at this dose revealed robust staining
in the RPE as well as in photoreceptor inner and outer
segments (Figure 2O).
As a means to quantitatively evaluate the amount of
reporter gene activity with viral dose, we performed a b-
galactosidase activity assay. We found that with an
increase in vector delivery, there was a statistically sig-
nificant increase in b-galactosidase activity (Figure 3).
Correspondingly, each vector dose group had a statisti-
cally significant difference in transgene activity from all
other vector dose groups (1-way ANOVA and Bonfer-
roni corrected pair-wise t-tests, p < 0.05). Additionally,
at each of the vector dose groups, b-galactosidase activ-
ity levels were also measured over different time points
and we found that overall there was no significant asso-
ciation between time points and transgene activity levels
(2-way ANOVA; dose p < 0.05; time p > 0.05; interac-
tion p > 0.05). These results demonstrate that there is a
significant correlation between viral vector dosage and
transgene expression.
Our results demonstrate that the viral vector delivery
resulted in a dose response trend in levels of the expres-
sion, as determined by histochemical (Figure 2) and
quantitative analyses (Figu r e3 ) .T h e s er e s u l t ss u g g e s t
that the vector dose can be used to control the level of
transgene expression. Another way to regulate the
amount of transgene expression is to use cis-acting
DNA elements and promoters. AAV vectors are gener-
ally unable to carry these large regulatory sequences,
but HD-Ad vectors with their large 37 kb cloning capa-
city can house multiple transgenes and native regulatory
elements that promote desirable gene expression. Speci-
fically, future studies will be directed to examine the
efficiency of HD-Ad vectors for targeting transgene
expression to photoreceptor cells using cell-specific
promoters.
Since potential tissue damage with high viral load is a
concern for retinal gene therapy, it is important to
determine the lowest amount of vector required for
maximum gene expression. To examine whether HD-Ad
vector delivery could cause tissue damage, we performed
H&E staining of the retinas from mice that received dif-
ferent doses of HD-Ad-CMV-LacZ. The eyes were first
processed for X-gal staining at 1 week post-injection to
verify that viral delivery was successful. The X-gal
stained retinal tissues were then used for H&E staining.
The results showed that at three increasing viral vector
concentrations, there was no visible sign of inflamma-
tion (retinal folding, granulations, cell death, and tissue
necrosis) (Figure 4A and 4B and 4C). Likewise, tissue
morphology of all injected mice were similar to their
negative, no-injection controls (Figure 4D), suggesting
that at the doses we selected, the viral vector concentra-
tion does not cause tissue damage. Our results show
that at 1 week following gene delivery, morphology of
the retina remains normal with little or no sign of tissue
damage or inflammation. Even at our highest viral vec-
tor dose, no visible inflammation was detected in the
ocular space, implying the absence of a strong immune
response. This lack of immunogenicity will lead to pro-
longed transgene expression in the host.
Conclusions
An ideal vector for retinal gene therapy needs to fulfill
the following criteria. First, it must be able to target
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the immune system from clearance of the vector as well
as prevent an immune reaction that may damage ocular
tissue. Third, it must be safe by avoiding insertional
tumorigenesis. Finally, it must retain a relatively large
cloning capacity for carrying large therapeutic genes as
well as long expression control DNA elements. While
great progress has been made with AAV based vectors,
it remains incapable of carrying large therapeutic genes.
The results of this study demonstrate that HD-Ad ful-
fills these requirements and has great potential for
further research as a vector for retinal gene therapy.
Methods
HD-Ad Vectors and their production
HD-Ad-CMV-LacZ[32] used in this study expresses the
LacZ reporter gene under the control of the cytomega-
lovirus immediate-early promoter (CMV). The reporter
Figure 2 Correlation of transgene expression with viral vector concentration. Mouse eyes were injected with 1 μL of a CMV LacZ vector
and enucleated at 2 weeks and processed for X-gal staining (B-D). Serial sections were cut at 6 μm and tissues were counterstained with neutral
red to reveal retinal layers (F-H). Controls with no vector injection (A, E, I) reveal no sign of b-galactosidase activity. Eyes injected at 1 × 10
7 vp/
μL (B, F, J) showed transgene expression to be present, but sporadic in the retina and confined to the RPE (M). At a higher dose of 1 × 10
8 vp/
μL (C, G, K) expression was seen around the entire retinal layer and detected in the RPE predominantly (N). At 1 × 10
9 vp/μL (D, H, L) significant
expression was detected around the entire retinal layer with staining in both the RPE layer as well as PR segments (O).
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[14] and the viral particles were prepared as described
[14,15]
Animal care and subretinal injection
One month old female CD-1 mice (Charles River
Laboratories International) used this study were treated
in strict compliance with the Association for Research
in Vision and Ophthalmology (ARVO) statement on the
Use of Animals in Ophthalmic and Vision Research.
The animal protocol was approved the Animal Care
Committee of the Hospital for Sick Children. For sub-
retinal vector delivery, animals were anaesthetized via
intraperitoneal injections of a mixture (100 μL/10 g
body mass) of ketamine (20 mg/mL; Wyeth Animal
Health), xylazine (2 mg/mL; Bayer HealthCare) in saline,
and pupils were dilated with a topical application of a
mixture of 0.2% Cyclogyl, 0.5% Mydfrin, and 0.1% Tro-
picamide (all from Alcon) in water for 30 seconds.
Under an SZX12 dissection microscope (Olympus), a
small incision was made through the cornea, adjacent to
the limbus with a 301/2-gauge needle. A 33 gauge
blunt-end needle (Hamilton) was then inserted through
the incision with special care to avoid the lens, and was
pushed through the retina to the subretinal space where
the virus was injected very slowly. Each animal received
1 μl of virus in the right eye, leaving the left eye as a
negative control. Partial retinal detachment was
observed and recovered in a week post-injection.
X-gal staining of whole eyeball
Eyes were enucleated and fixed with 1% formaldehyde,
0.1% glutaraldehyde, 2 mM MgCl2, 5 mM EGTA in 0.1
M sodium phosphate buffer, pH 7.8 for 30 minutes at 4°
C with rocking. Fixed tissues were washed with 2 mM
MgCl2, 0.01% Deoxycholate, 0.02% NP-40 in 0.1 M
sodium phosphate buffer at 4°C with rocking and
stained with X-gal in the wash solution containing 5
mM K4Fe(CN)6,5m MK 3Fe(CN)6 and 40 mg/ml of
dimethyl formaide) at 37°C with shaking for 3 hours.
After staining, samples were washed 3 times with 70%
ethanol and post-fixed with 10% formaldehyde at 4°C
for 4 hours. Samples were then sent to the Pathology
Department of The Hospital for Sick Children where
they were embedded in paraffin blocks. 60 serial sec-
tions (6 μm thick) were then cut at the horizontal meri-
dian and distributed on 10 slides representative of the
whole eye at different levels. Light microscope images
were taken on a DM IRB microscope (Leica). Four eyes
were examined at 1 week, and 3 eyes at each of 2
weeks, 1 month, and 2 months. The un-injected eye of
each animal was used as controls.
Histology analysis
For H&E staining, tissues were deparaffinised and rehy-
drated in a series of alcohol rehydration steps. Slides
were stained with hematoxalin (Poly Scientific) for 3
minutes and rinsed with deionized water. Tissues were
dipped briefly in acidified ethanol (1 mL of concentrated
HCl in 700 mL of 70% ethanol) to de-stain and rinsed
with deionized water. Excess water was blotted from the
slide before staining tissue with eosin (Poly Scientific)
for 1 minute. Tissues were dehydrated in a series of
alcohol dehydration steps and mounted with xylene-
based mounting media, Permount (Fisher Scientific) and
covered with a coverslip. For neutral red staining, tissues
were deparaffinised and rehydrated in a series of alcohol
rehydration steps. Slides were stained with neutral red
staining solution (0.1% neutral red in 37 mM acetate
solution, pH4.8) for 2 minutes and rinsed in running
tap water until dye has been removed from slides. Tis-
sues were dehydrated in a series of alcohol dehydration
steps and mounted with xylene-based mounting media,
Permount (Fisher Scientific) and covered with a
coverslip.
b-Galactosidase reporter assays
Eyes were enucleated and the lens and vitreous was
removed under a dissection microscope, leaving only the
eyecup. Tissue was homogenized in lysis buffer
Figure 3 Quantitative analysis of vector dose-dependent
transgene expression. Mouse eyes were injected with 1 μLo fa
CMV LacZ vector at increasing concentrations of 1 × 10
7 vp/μL, 1 ×
10
8 vp/μL and 1 × 10
9 vp/μL. Eyes were enucleated, processed for
X-gal staining and measured for b-galactosidase activity levels.
Transgene expression was determined by luminescence and
reported as a fold increase relative to the control. Statistical analysis
revealed no significant difference between the time points.
However, activity levels were determined to be significantly different
with the increase in viral vector dose suggesting that a dose-
dependent relationship exists (2-way ANOVA; dose p < 0.05; time p
> 0.05; interaction p>0.05). Error bars indicate standard error of the
mean (SEM) and 4 mice were used for each time point of each
vector dose.
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with 0.5 mM DTT, 10% Triton X-100 and proteinase
inhibitor cocktail (Roche Diagnostics). Samples were
centrifuged for 15 minutes at 12,000 RPM in 4°C.
Supernatant was collected and either processed immedi-
ately or stored at -80°C. The lysate was heat inactivated
at 48°C for 50 minutes and allowed to cool to room
temperature. The b-galactosidase activity was measured
using a chemiluminescent assay as described [33]. Four
eyes were used for each time point at each dosage level
(total of 64 eyes).
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